Androgenetic Alopecia Treatment Guidelines

First-Line Therapy

The American Academy of Dermatology recommends topical minoxidil (5% for women, 5% for men) as the established first-line pharmacologic treatment for androgenetic alopecia, with demonstrated efficacy in randomized controlled trials 1, 2, 3.
Topical minoxidil requires twice-daily use continuously to maintain hair growth, as measurable changes disappear within months after discontinuation, although the exact duration is not specified in the provided references 1, 2, 3.

The American Academy of Dermatology suggests that low-dose oral minoxidil (1 mg daily) may be considered for patients who cannot tolerate or comply with topical formulations, though it requires cardiovascular screening 4, 5.
Oral minoxidil must be avoided in patients with cardiovascular disease, and all patients require screening for cardiovascular conditions before initiation, according to the American Academy of Dermatology 4, 5.

The American Academy of Dermatology reports that PRP (platelet-rich plasma) combined with topical 5% minoxidil is more effective than either treatment alone for androgenetic alopecia, particularly useful in poor responders to conventional therapy 2, 3, 6.
Treatment protocols typically involve PRP injections every 3-6 months combined with daily topical minoxidil application, as recommended by the American Academy of Dermatology 2, 3, 6.

Patients must understand that no treatment alters the underlying course of androgenetic alopecia—all treatments require continuous use to maintain benefit, as stated by the British Journal of Dermatology 7.
Hair regrowth cannot be expected within 3 months of starting treatment; realistic timelines are 6-12 months for visible improvement, according to the British Journal of Dermatology 7.

Women have a higher overall incidence of adverse effects with oral minoxidil compared to men and require lower starting doses, as reported by the American Academy of Dermatology 5.

Screen all patients for cardiovascular disease before initiating oral minoxidil, including assessment for orthostatic symptoms, edema, and tachycardia, as recommended by the American Academy of Dermatology 4, 5.
Monitor for rare but serious adverse effects including pericardial effusion, particularly in patients with pre-existing cardiovascular conditions, according to the American Academy of Dermatology 4, 5.

The combination of platelet-rich plasma (PRP) with topical 5% minoxidil is the most effective treatment modality, showing highly significant increases in hair density at 3-5 months, according to the Periodontology 2000 guidelines 8, 9, 10
Complex therapy (PRP with minoxidil) increased hair density by 1.74 times and hair diameter by 14.3 times compared to minoxidil monotherapy, as reported in Periodontology 2000 8, 9, 10
PRP is not superior to minoxidil alone in treating moderate grades of androgenetic alopecia, with no significant difference in total hair count, terminal hair count, and density, according to Periodontology 2000 8, 9, 10, 11
Minoxidil is better tolerated than PRP (less pain) when comparing monotherapies, as stated in Periodontology 2000 8, 9, 10, 11

Minoxidil will not improve alopecia areata effectively, with variable response rates of only 32-33% in alopecia areata, and neither minoxidil nor spironolactone is considered first-line therapy for this condition, according to the British Journal of Dermatology 12, 13

The American Academy of Dermatology recommends combining topical minoxidil 5% twice daily with platelet-rich plasma (PRP) injections, which increases hair density by 1.74 times compared to minoxidil monotherapy 14, 15, 16

The National Institute of Health suggests that oral minoxidil 0.25-1 mg daily is as effective as topical 5% minoxidil for pattern hair loss, but requires cardiovascular screening before initiation 14